These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 29453696)

  • 1. Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance.
    Oikonomou E; Mourouzis K; Fountoulakis P; Papamikroulis GA; Siasos G; Antonopoulos A; Vogiatzi G; Tsalamadris S; Vavuranakis M; Tousoulis D
    Heart Fail Rev; 2018 May; 23(3):389-408. PubMed ID: 29453696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptors as therapeutic targets for heart failure.
    Abushouk AI; El-Husseny MWA; Bahbah EI; Elmaraezy A; Ali AA; Ashraf A; Abdel-Daim MM
    Biomed Pharmacother; 2017 Nov; 95():692-700. PubMed ID: 28886529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac metabolism, inflammation, and peroxisome proliferator-activated receptors modulated by 1,25-dihydroxyvitamin D3 in diabetic rats.
    Lee TI; Kao YH; Chen YC; Tsai WC; Chung CC; Chen YJ
    Int J Cardiol; 2014 Sep; 176(1):151-7. PubMed ID: 25062566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator activator receptors (PPAR), insulin resistance, and cardiomyopathy: friends or foes for the diabetic patient with heart failure?
    Nikolaidis LA; Levine TB
    Cardiol Rev; 2004; 12(3):158-70. PubMed ID: 15078585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How Diabetes and Heart Failure Modulate Each Other and Condition Management.
    Randhawa VK; Dhanvantari S; Connelly KA
    Can J Cardiol; 2021 Apr; 37(4):595-608. PubMed ID: 33276047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPARs modulate cardiac metabolism and mitochondrial function in diabetes.
    Lee TW; Bai KJ; Lee TI; Chao TF; Kao YH; Chen YJ
    J Biomed Sci; 2017 Jan; 24(1):5. PubMed ID: 28069019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiomyopathy in type 2 diabetes: update on pathophysiological mechanisms.
    Saunders J; Mathewkutty S; Drazner MH; McGuire DK
    Herz; 2008 Apr; 33(3):184-90. PubMed ID: 18568312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptors modulate cardiac dysfunction in diabetic cardiomyopathy.
    Lee TI; Kao YH; Chen YC; Huang JH; Hsiao FC; Chen YJ
    Diabetes Res Clin Pract; 2013 Jun; 100(3):330-9. PubMed ID: 23369225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Histone Deacetylase Inhibitor Modulates Cardiac Peroxisome Proliferator-Activated Receptors and Inflammatory Cytokines in Heart Failure.
    Lkhagva B; Lin YK; Kao YH; Chazo TF; Chung CC; Chen SA; Chen YJ
    Pharmacology; 2015; 96(3-4):184-91. PubMed ID: 26304494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The metabolic syndrome: relationship between insulin sensitivity and the role of peroxisome proliferator-activated receptors (PPARs) in saccharide and lipid metabolism.
    Yahia RB; Lichnovská R; Brychta T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):237-41. PubMed ID: 16601762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of PPARs in Pathological Cardiac Hypertrophy and Heart Failure.
    Liao HH; Jia XH; Liu HJ; Yang Z; Tang QZ
    Curr Pharm Des; 2017; 23(11):1677-1686. PubMed ID: 27779079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.
    Palomer X; Salvadó L; Barroso E; Vázquez-Carrera M
    Int J Cardiol; 2013 Oct; 168(4):3160-72. PubMed ID: 23932046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
    Franko A; Neschen S; Rozman J; Rathkolb B; Aichler M; Feuchtinger A; Brachthäuser L; Neff F; Kovarova M; Wolf E; Fuchs H; Häring HU; Peter A; Hrabě de Angelis M
    Mol Metab; 2017 Mar; 6(3):256-266. PubMed ID: 28271032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac Insulin Resistance in Heart Failure: The Role of Mitochondrial Dynamics.
    Saotome M; Ikoma T; Hasan P; Maekawa Y
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential impact of SGLT2 inhibitors on left ventricular diastolic function in patients with diabetes mellitus.
    Tanaka H; Hirata KI
    Heart Fail Rev; 2018 May; 23(3):439-444. PubMed ID: 29330646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARs-Orchestrated Metabolic Homeostasis in the Adipose Tissue.
    Sun C; Mao S; Chen S; Zhang W; Liu C
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisomes in cardiomyocytes and the peroxisome / peroxisome proliferator-activated receptor-loop.
    Colasante C; Chen J; Ahlemeyer B; Baumgart-Vogt E
    Thromb Haemost; 2015 Mar; 113(3):452-63. PubMed ID: 25608554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
    Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.